sofosbuvir/velpatasvir (epclusa) for hepatitis c sofosbuvir-velpatasvir (epclusa) 400-100 mg tablet wac price of epclusa what is the price of epclusa Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Generic Epclusa - MassHealth has directly negotiated with six drug manufacturers over the price of 12 drugs, which has saved the agency a net of $13 million. Thats the gist of a deal the Massachusetts Medicaid program, MassHealth, has reached for one of the most expensive drugs on the market. MassHealth has directly negotiated with six drug manufacturers over the price of 12 drugs, which has saved the agency a net of $13 million. We think it makes sense to pay for innovation for a drug that could really work. And we think the Commonwealth, with public dollars, should not pay for something if it doesnt do what its advertised to do, said MassHealth director Dan Tsai. MassHealth will pay slightly less than $2 million for each Zolgensma infusion, which Tsai called a fair price for approved patients: children under two years of age. The condition the drug treats is rare Novartis expects to administer about State payments, evaluations and refunds if the drug is not effective would stretch over five years. Novartis routinely offers a five-year for Zolgensma. The company saidin a statement that theseso-called value-based or outcomes-based agreements are becoming routine as well. It saysit is in 'active discussions' with Massachusetts. We recognize innovative therapies like Zolgensma require innovative solutions for access, a Novartis spokesperson said. is one of just a few states with approval from the Centers for Medicare and Medicaid Services to pursue these deals. Thats one reason this one is important, said Matt Salo, executive director at the National Association of Medicaid Directors. Massachusetts is kind of the vanguard on a lot of these prescription drug pricing issues, Salo said. They are blazing a trail that every other state is watching and saying, if Massachusetts can make this work, we think we can do it too. Salo said complicated and restrictive drug pricing rules may get in the way. Take whats known as the best price rule. Medicaid programs have to cover all approved drugs, but they dont have to pay more than the lowest, or best, price on the market. Theres some concern that if Massachusetts, for example, were to pay just a fraction of Zolgensmas list price in a case where the drug didnt work, that would become a new best price, he said. While some argue thats the letter of the law, its not the spirit of the law, Salo said, So to me it strains credulity. Drug costs are a national concern, especially for states said Rachel Dolan, senior policy analyst at the Kaiser Family. So states are looking for alternative ways to pay for drugs, particularly new breakthrough drugs that come with large price tags. Dolan said its too early to know if any of these new drug pricing strategies will help state Medicaid programs save money. baisse de prix epclusa epclusa 400 mg/100 mg prix epclusa prix au maroc epclusa prix belgique epclusa prix canada epclusa prix en france epclusa prix suisse prix du medicament epclusa ipr@tempemail.daniel-james.me